Abstract:figure legend Physiological influences of OXM and its emerging insights from evidence on bariatric surgery effects. CCK, cholecystokinin; FGF21, fibroblast growth factor 21; GLUT4, glucose transporter type 4; IRS1, insulin receptor substrate‐1; NNMT, nicotinamide N‐methyltransferase; OXM, oxyntomodulin Incretins, such as glucagon‐like peptide‐1 (GLP1) and glucose‐dependent insulinotropic polypeptide (GIP), have advanced the treatment landscape of obesity to a new pinnacle. As opposed to singular incretin effects, oxyntomodulin (OXM) activates glucagon receptors (GCGR) and glucagon‐like peptide‐1 receptors (GLP1R), demonstrating a more dynamic range of effects that are more likely to align with evolving 'health gains' goals in obesity care. Here, we will review the molecular insights from their inception to recent developments and challenges. This review will discuss the physiological actions of OXM, primarily appetite regulation, energy expenditure, and glucose homeostasis. Finally, we will shed light on the development of OXM‐based therapies for obesity and associated complications, and outline important considerations for more translational efforts.

Oxyntomodulin physiology and its therapeutic development in obesity and associated complications